BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Beljanski V, Lewis CS, Smith CD. Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts. Cancer Biol Ther 2011;11:524-34. [PMID: 21258214 DOI: 10.4161/cbt.11.5.14677] [Cited by in Crossref: 68] [Cited by in F6Publishing: 60] [Article Influence: 6.2] [Reference Citation Analysis]
Number Citing Articles
1 Paul B, Lewinska M, Andersen JB. Lipid alterations in chronic liver disease and liver cancer. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100479] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
2 Masucci MT, Minopoli M, Di Carluccio G, Motti ML, Carriero MV. Therapeutic Strategies Targeting Urokinase and Its Receptor in Cancer. Cancers (Basel) 2022;14:498. [PMID: 35158766 DOI: 10.3390/cancers14030498] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Fukuyama K, Asagiri M, Sugimoto M, Tsushima H, Seo S, Taura K, Uemoto S, Iwaisako K. Gene expression profiles of liver cancer cell lines reveal two hepatocyte-like and fibroblast-like clusters. PLoS One 2021;16:e0245939. [PMID: 33539378 DOI: 10.1371/journal.pone.0245939] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Ding T, Zhi Y, Xie W, Yao Q, Liu B. Rational design of SphK inhibitors using crystal structures aided by computer. Eur J Med Chem 2021;213:113164. [PMID: 33454547 DOI: 10.1016/j.ejmech.2021.113164] [Reference Citation Analysis]
5 Shi W, Zhang S, Ma D, Yan D, Zhang G, Cao Y, Wang Z, Wu J, Jiang C. Targeting SphK2 Reverses Acquired Resistance of Regorafenib in Hepatocellular Carcinoma. Front Oncol 2020;10:694. [PMID: 32670862 DOI: 10.3389/fonc.2020.00694] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
6 Badroon NA, Abdul Majid N, Alshawsh MA. Antiproliferative and Apoptotic Effects of Cardamonin against Hepatocellular Carcinoma HepG2 Cells. Nutrients 2020;12:E1757. [PMID: 32545423 DOI: 10.3390/nu12061757] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
7 Kroll A, Cho HE, Kang MH. Antineoplastic Agents Targeting Sphingolipid Pathways. Front Oncol 2020;10:833. [PMID: 32528896 DOI: 10.3389/fonc.2020.00833] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
8 Jakobi K, Beyer S, Koch A, Thomas D, Schwalm S, Zeuzem S, Pfeilschifter J, Grammatikos G. Sorafenib Treatment and Modulation of the Sphingolipid Pathway Affect Proliferation and Viability of Hepatocellular Carcinoma In Vitro. Int J Mol Sci 2020;21:E2409. [PMID: 32244391 DOI: 10.3390/ijms21072409] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
9 Ishay Y, Nachman D, Khoury T, Ilan Y. The role of the sphingolipid pathway in liver fibrosis: an emerging new potential target for novel therapies. Am J Physiol Cell Physiol 2020;318:C1055-64. [PMID: 32130072 DOI: 10.1152/ajpcell.00003.2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
10 Magli E, Corvino A, Fiorino F, Frecentese F, Perissutti E, Saccone I, Santagada V, Caliendo G, Severino B. Design of Sphingosine Kinases Inhibitors: Challenges and Recent Developments. Curr Pharm Des 2019;25:956-68. [PMID: 30947653 DOI: 10.2174/1381612825666190404115424] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
11 Sukocheva OA, Furuya H, Ng ML, Friedemann M, Menschikowski M, Tarasov VV, Chubarev VN, Klochkov SG, Neganova ME, Mangoni AA, Aliev G, Bishayee A. Sphingosine kinase and sphingosine-1-phosphate receptor signaling pathway in inflammatory gastrointestinal disease and cancers: A novel therapeutic target. Pharmacol Ther 2020;207:107464. [PMID: 31863815 DOI: 10.1016/j.pharmthera.2019.107464] [Cited by in Crossref: 54] [Cited by in F6Publishing: 45] [Article Influence: 18.0] [Reference Citation Analysis]
12 Liu Y, Zhi Y, Song H, Zong M, Yi J, Mao G, Chen L, Huang G. S1PR1 promotes proliferation and inhibits apoptosis of esophageal squamous cell carcinoma through activating STAT3 pathway. J Exp Clin Cancer Res. 2019;38:369. [PMID: 31438989 DOI: 10.1186/s13046-019-1369-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 6.7] [Reference Citation Analysis]
13 Alshaker H, Wang Q, Brewer D, Pchejetski D. Transcriptome-Wide Effects of Sphingosine Kinases Knockdown in Metastatic Prostate and Breast Cancer Cells: Implications for Therapeutic Targeting. Front Pharmacol 2019;10:303. [PMID: 30971929 DOI: 10.3389/fphar.2019.00303] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
14 Dong J, Geng J, Tan W. MiR-363-3p suppresses tumor growth and metastasis of colorectal cancer via targeting SphK2. Biomed Pharmacother 2018;105:922-31. [PMID: 30021386 DOI: 10.1016/j.biopha.2018.06.052] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
15 Lewis CS, Voelkel-Johnson C, Smith CD. Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640. Oncotarget 2016;7:60181-92. [PMID: 27517489 DOI: 10.18632/oncotarget.11112] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
16 Xie V, Tong D, Wallington-Beddoe CT, Bradstock KF, Bendall LJ. Sphingosine kinase 2 supports the development of BCR/ABL-independent acute lymphoblastic leukemia in mice. Biomark Res 2018;6:6. [PMID: 29441205 DOI: 10.1186/s40364-018-0120-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
17 Ding X, Chaiteerakij R, Moser CD, Shaleh H, Boakye J, Chen G, Ndzengue A, Li Y, Zhou Y, Huang S, Sinicrope FA, Zou X, Thomas MB, Smith CD, Roberts LR. Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells. Oncotarget. 2016;7:20080-20092. [PMID: 26956050 DOI: 10.18632/oncotarget.7914] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 5.5] [Reference Citation Analysis]
18 Huwiler A, Pfeilschifter J. Sphingolipid signaling in renal fibrosis. Matrix Biol 2018;68-69:230-47. [PMID: 29343457 DOI: 10.1016/j.matbio.2018.01.006] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
19 Zeng Y, Liu X, Yan Z, Xie L. Sphingosine 1-phosphate regulates proliferation, cell cycle and apoptosis of hepatocellular carcinoma cells via syndecan-1. Prog Biophys Mol Biol 2019;148:32-8. [PMID: 29180036 DOI: 10.1016/j.pbiomolbio.2017.11.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
20 Ogretmen B. Sphingolipid metabolism in cancer signalling and therapy. Nat Rev Cancer 2018;18:33-50. [PMID: 29147025 DOI: 10.1038/nrc.2017.96] [Cited by in Crossref: 343] [Cited by in F6Publishing: 422] [Article Influence: 68.6] [Reference Citation Analysis]
21 Morchang A, Lee RCH, Yenchitsomanus PT, Sreekanth GP, Noisakran S, Chu JJH, Limjindaporn T. RNAi screen reveals a role of SPHK2 in dengue virus-mediated apoptosis in hepatic cell lines. PLoS One 2017;12:e0188121. [PMID: 29145490 DOI: 10.1371/journal.pone.0188121] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
22 Hait NC, Maiti A. The Role of Sphingosine-1-Phosphate and Ceramide-1-Phosphate in Inflammation and Cancer. Mediators Inflamm 2017;2017:4806541. [PMID: 29269995 DOI: 10.1155/2017/4806541] [Cited by in Crossref: 76] [Cited by in F6Publishing: 89] [Article Influence: 15.2] [Reference Citation Analysis]
23 Pyne NJ, Adams DR, Pyne S. Sphingosine Kinase 2 in Autoimmune/Inflammatory Disease and the Development of Sphingosine Kinase 2 Inhibitors. Trends in Pharmacological Sciences 2017;38:581-91. [DOI: 10.1016/j.tips.2017.04.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
24 Kwong EK, Li X, Hylemon PB, Zhou H. Sphingosine Kinases/Sphingosine 1-Phosphate Signaling in Hepatic Lipid Metabolism. Curr Pharmacol Rep 2017;3:176-83. [PMID: 29130028 DOI: 10.1007/s40495-017-0093-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
25 Grbčić P, Tomljanović I, Klobučar M, Kraljević Pavelić S, Lučin K, Sedić M. Dual sphingosine kinase inhibitor SKI-II enhances sensitivity to 5-fluorouracil in hepatocellular carcinoma cells via suppression of osteopontin and FAK/IGF-1R signalling. Biochemical and Biophysical Research Communications 2017;487:782-8. [DOI: 10.1016/j.bbrc.2017.04.100] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
26 Xie Z, Liu H, Geng M. Targeting sphingosine-1-phosphate signaling for cancer therapy. Sci China Life Sci 2017;60:585-600. [DOI: 10.1007/s11427-017-9046-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
27 Dany M. Sphingosine metabolism as a therapeutic target in cutaneous melanoma. Transl Res 2017;185:1-12. [PMID: 28528915 DOI: 10.1016/j.trsl.2017.04.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
28 Britten CD, Garrett-Mayer E, Chin SH, Shirai K, Ogretmen B, Bentz TA, Brisendine A, Anderton K, Cusack SL, Maines LW, Zhuang Y, Smith CD, Thomas MB. A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors. Clin Cancer Res 2017;23:4642-50. [PMID: 28420720 DOI: 10.1158/1078-0432.CCR-16-2363] [Cited by in Crossref: 69] [Cited by in F6Publishing: 84] [Article Influence: 13.8] [Reference Citation Analysis]
29 Grammatikos G, Schoell N, Ferreirós N, Bon D, Herrmann E, Farnik H, Köberle V, Piiper A, Zeuzem S, Kronenberger B, Waidmann O, Pfeilschifter J. Serum sphingolipidomic analyses reveal an upregulation of C16-ceramide and sphingosine-1-phosphate in hepatocellular carcinoma. Oncotarget 2016;7:18095-105. [PMID: 26933996 DOI: 10.18632/oncotarget.7741] [Cited by in Crossref: 41] [Cited by in F6Publishing: 47] [Article Influence: 8.2] [Reference Citation Analysis]
30 Nath LR, Gorantla JN, Thulasidasan AK, Vijayakurup V, Shah S, Anwer S, Joseph SM, Antony J, Veena KS, Sundaram S, Marelli UK, Lankalapalli RS, Anto RJ. Evaluation of uttroside B, a saponin from Solanum nigrum Linn, as a promising chemotherapeutic agent against hepatocellular carcinoma. Sci Rep 2016;6:36318. [PMID: 27808117 DOI: 10.1038/srep36318] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
31 Pitman MR, Costabile M, Pitson SM. Recent advances in the development of sphingosine kinase inhibitors. Cellular Signalling 2016;28:1349-63. [DOI: 10.1016/j.cellsig.2016.06.007] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 10.0] [Reference Citation Analysis]
32 Vogt D, Stark H. Therapeutic Strategies and Pharmacological Tools Influencing S1P Signaling and Metabolism. Med Res Rev 2017;37:3-51. [PMID: 27480072 DOI: 10.1002/med.21402] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
33 Evangelisti C, Evangelisti C, Buontempo F, Lonetti A, Orsini E, Chiarini F, Barata JT, Pyne S, Pyne NJ, Martelli AM. Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies. Leukemia 2016;30:2142-51. [PMID: 27461062 DOI: 10.1038/leu.2016.208] [Cited by in Crossref: 17] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
34 Nagahashi M, Yuza K, Hirose Y, Nakajima M, Ramanathan R, Hait NC, Hylemon PB, Zhou H, Takabe K, Wakai T. The roles of bile acids and sphingosine-1-phosphate signaling in the hepatobiliary diseases. J Lipid Res 2016;57:1636-43. [PMID: 27459945 DOI: 10.1194/jlr.R069286] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 7.3] [Reference Citation Analysis]
35 Prieto-Domínguez N, Ordóñez R, Fernández A, García-Palomo A, Muntané J, González-Gallego J, Mauriz JL. Modulation of Autophagy by Sorafenib: Effects on Treatment Response. Front Pharmacol 2016;7:151. [PMID: 27375485 DOI: 10.3389/fphar.2016.00151] [Cited by in Crossref: 54] [Cited by in F6Publishing: 70] [Article Influence: 9.0] [Reference Citation Analysis]
36 Kiraz Y, Adan A, Kartal Yandim M, Baran Y. Major apoptotic mechanisms and genes involved in apoptosis. Tumour Biol. 2016;37:8471-8486. [PMID: 27059734 DOI: 10.1007/s13277-016-5035-9] [Cited by in Crossref: 223] [Cited by in F6Publishing: 272] [Article Influence: 37.2] [Reference Citation Analysis]
37 Pyne S, Adams DR, Pyne NJ. Sphingosine 1-phosphate and sphingosine kinases in health and disease: Recent advances. Prog Lipid Res 2016;62:93-106. [PMID: 26970273 DOI: 10.1016/j.plipres.2016.03.001] [Cited by in Crossref: 114] [Cited by in F6Publishing: 106] [Article Influence: 19.0] [Reference Citation Analysis]
38 Uranbileg B, Ikeda H, Kurano M, Enooku K, Sato M, Saigusa D, Aoki J, Ishizawa T, Hasegawa K, Kokudo N, Yatomi Y. Increased mRNA Levels of Sphingosine Kinases and S1P Lyase and Reduced Levels of S1P Were Observed in Hepatocellular Carcinoma in Association with Poorer Differentiation and Earlier Recurrence. PLoS One 2016;11:e0149462. [PMID: 26886371 DOI: 10.1371/journal.pone.0149462] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 5.5] [Reference Citation Analysis]
39 Aurelio L, Scullino CV, Pitman MR, Sexton A, Oliver V, Davies L, Rebello RJ, Furic L, Creek DJ, Pitson SM, Flynn BL. From Sphingosine Kinase to Dihydroceramide Desaturase: A Structure-Activity Relationship (SAR) Study of the Enzyme Inhibitory and Anticancer Activity of 4-((4-(4-Chlorophenyl)thiazol-2-yl)amino)phenol (SKI-II). J Med Chem 2016;59:965-84. [PMID: 26780304 DOI: 10.1021/acs.jmedchem.5b01439] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 6.3] [Reference Citation Analysis]
40 Venant H, Rahmaniyan M, Jones EE, Lu P, Lilly MB, Garrett-Mayer E, Drake RR, Kraveka JM, Smith CD, Voelkel-Johnson C. The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo. Mol Cancer Ther 2015;14:2744-52. [PMID: 26494858 DOI: 10.1158/1535-7163.MCT-15-0279] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 7.3] [Reference Citation Analysis]
41 Venkata JK, An N, Stuart R, Costa LJ, Cai H, Coker W, Song JH, Gibbs K, Matson T, Garrett-Mayer E, Wan Z, Ogretmen B, Smith C, Kang Y. Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma. Blood 2014;124:1915-25. [PMID: 25122609 DOI: 10.1182/blood-2014-03-559385] [Cited by in Crossref: 56] [Cited by in F6Publishing: 62] [Article Influence: 8.0] [Reference Citation Analysis]
42 Ahmed D, de Verdier PJ, Ryk C, Lunqe O, Stål P, Flygare J. FTY720 (Fingolimod) sensitizes hepatocellular carcinoma cells to sorafenib-mediated cytotoxicity. Pharmacol Res Perspect 2015;3:e00171. [PMID: 26516583 DOI: 10.1002/prp2.171] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
43 Adada MM, Canals D, Jeong N, Kelkar AD, Hernandez-Corbacho M, Pulkoski-Gross MJ, Donaldson JC, Hannun YA, Obeid LM. Intracellular sphingosine kinase 2-derived sphingosine-1-phosphate mediates epidermal growth factor-induced ezrin-radixin-moesin phosphorylation and cancer cell invasion. FASEB J 2015;29:4654-69. [PMID: 26209696 DOI: 10.1096/fj.15-274340] [Cited by in Crossref: 45] [Cited by in F6Publishing: 50] [Article Influence: 6.4] [Reference Citation Analysis]
44 Santos WL, Lynch KR. Drugging sphingosine kinases. ACS Chem Biol 2015;10:225-33. [PMID: 25384187 DOI: 10.1021/cb5008426] [Cited by in Crossref: 75] [Cited by in F6Publishing: 68] [Article Influence: 10.7] [Reference Citation Analysis]
45 Dai L, Plaisance-Bonstaff K, Voelkel-Johnson C, Smith CD, Ogretmen B, Qin Z, Parsons C. Sphingosine kinase-2 maintains viral latency and survival for KSHV-infected endothelial cells. PLoS One 2014;9:e102314. [PMID: 25010828 DOI: 10.1371/journal.pone.0102314] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
46 Plano D, Amin S, Sharma AK. Importance of sphingosine kinase (SphK) as a target in developing cancer therapeutics and recent developments in the synthesis of novel SphK inhibitors. J Med Chem 2014;57:5509-24. [PMID: 24471412 DOI: 10.1021/jm4011687] [Cited by in Crossref: 67] [Cited by in F6Publishing: 70] [Article Influence: 8.4] [Reference Citation Analysis]
47 Truman JP, García-Barros M, Obeid LM, Hannun YA. Evolving concepts in cancer therapy through targeting sphingolipid metabolism. Biochim Biophys Acta. 2014;1841:1174-1188. [PMID: 24384461 DOI: 10.1016/j.bbalip.2013.12.013] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 8.1] [Reference Citation Analysis]
48 Qin Z, Dai L, Trillo-Tinoco J, Senkal C, Wang W, Reske T, Bonstaff K, Del Valle L, Rodriguez P, Flemington E, Voelkel-Johnson C, Smith CD, Ogretmen B, Parsons C. Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma. Mol Cancer Ther 2014;13:154-64. [PMID: 24140934 DOI: 10.1158/1535-7163.MCT-13-0466] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 4.2] [Reference Citation Analysis]
49 Neubauer HA, Pitson SM. Roles, regulation and inhibitors of sphingosine kinase 2. FEBS J 2013;280:5317-36. [PMID: 23638983 DOI: 10.1111/febs.12314] [Cited by in Crossref: 116] [Cited by in F6Publishing: 118] [Article Influence: 12.9] [Reference Citation Analysis]
50 Savić R, He X, Fiel I, Schuchman EH. Recombinant human acid sphingomyelinase as an adjuvant to sorafenib treatment of experimental liver cancer. PLoS One 2013;8:e65620. [PMID: 23724146 DOI: 10.1371/journal.pone.0065620] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
51 Wallington-Beddoe CT, Bradstock KF, Bendall LJ. Oncogenic properties of sphingosine kinases in haematological malignancies. Br J Haematol 2013;161:623-38. [PMID: 23521541 DOI: 10.1111/bjh.12302] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
52 Liu K, Guo TL, Hait NC, Allegood J, Parikh HI, Xu W, Kellogg GE, Grant S, Spiegel S, Zhang S. Biological characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) as a selective sphingosine kinase-2 inhibitor and anticancer agent. PLoS One 2013;8:e56471. [PMID: 23437140 DOI: 10.1371/journal.pone.0056471] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 5.9] [Reference Citation Analysis]
53 Chan H, Pitson SM. Post-translational regulation of sphingosine kinases. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2013;1831:147-56. [DOI: 10.1016/j.bbalip.2012.07.005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
54 Sun WY, Bonder CS. Sphingolipids: a potential molecular approach to treat allergic inflammation. J Allergy (Cairo) 2012;2012:154174. [PMID: 23316248 DOI: 10.1155/2012/154174] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
55 Kharel Y, Raje M, Gao M, Gellett AM, Tomsig JL, Lynch KR, Santos WL. Sphingosine kinase type 2 inhibition elevates circulating sphingosine 1-phosphate. Biochem J 2012;447:149-57. [PMID: 22747486 DOI: 10.1042/BJ20120609] [Cited by in Crossref: 70] [Cited by in F6Publishing: 70] [Article Influence: 7.0] [Reference Citation Analysis]
56 Gao P, Peterson YK, Smith RA, Smith CD. Characterization of isoenzyme-selective inhibitors of human sphingosine kinases. PLoS One 2012;7:e44543. [PMID: 22970244 DOI: 10.1371/journal.pone.0044543] [Cited by in Crossref: 74] [Cited by in F6Publishing: 76] [Article Influence: 7.4] [Reference Citation Analysis]
57 Orr Gandy KA, Obeid LM. Targeting the sphingosine kinase/sphingosine 1-phosphate pathway in disease: review of sphingosine kinase inhibitors. Biochim Biophys Acta 2013;1831:157-66. [PMID: 22801037 DOI: 10.1016/j.bbalip.2012.07.002] [Cited by in Crossref: 83] [Cited by in F6Publishing: 82] [Article Influence: 8.3] [Reference Citation Analysis]
58 Stevenson CE, Takabe K, Nagahashi M, Milstien S, Spiegel S. Targeting sphingosine-1-phosphate in hematologic malignancies. Anticancer Agents Med Chem 2011;11:794-8. [PMID: 21707492 DOI: 10.2174/187152011797655122] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
59 Pchejetski D, Böhler T, Stebbing J, Waxman J. Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer. Nat Rev Urol 2011;8:569-678. [PMID: 21912422 DOI: 10.1038/nrurol.2011.117] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
60 Gao P, Smith CD. Ablation of sphingosine kinase-2 inhibits tumor cell proliferation and migration. Mol Cancer Res 2011;9:1509-19. [PMID: 21896638 DOI: 10.1158/1541-7786.MCR-11-0336] [Cited by in Crossref: 80] [Cited by in F6Publishing: 74] [Article Influence: 7.3] [Reference Citation Analysis]